Volume 153, Issue 1, Pages (April 2019)

Slides:

Advertisements

Similar presentations

Volume 144, Issue 1, Pages (January 2017)

Advertisements

Thymic Epithelial Tumors: Prognostic Determinants Among Clinical, Histopathologic, and Computed Tomography Findings Jung Won Moon, MD, Kyung Soo Lee,

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer C.E. Henry, C. Emmanuel, N.

Volume 145, Issue 1, Pages (April 2017)

Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade.

Khaled M. Madbouly, Abdrabou N. Mashhour, Waleed Omar

Volume 144, Issue 3, Pages (March 2013)

Volume 150, Issue 1, Pages (July 2018)

NFATc1 Expression as a Prognosticator in Urothelial Carcinoma of the Upper Urinary Tract Takashi Kawahara, Satoshi Inoue, Kazutoshi Fujita, Taichi Mizushima,

Are patients willing to travel for better ovarian cancer care?

L. C. Parsons, S. A. Sullivan, C. Garcia, T. Castellano, V. L

Volume 148, Issue 1, Pages (January 2018)

Volume 150, Issue 3, Pages (September 2018)

Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803 Akira Inoue,

Volume 138, Issue 1, Pages (July 2015)

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Unusual Thickened Gastric Folds in a Patient With Breast Cancer

Volume 141, Issue 1, Pages 2-9 (April 2016)

Volume 141, Issue 2, Pages (May 2016)

Volume 135, Issue 1, Pages (October 2014)

M. Ulm, D. Lee, A.R. Mabe, M.P. Lowe, S. Kumar, T. Tillmanns

Wilberto Nieves-Neira, J. Julie Kim, Daniela Matei

Volume 136, Issue 2, Pages (February 2015)

Volume 145, Issue 2, Pages (May 2017)

Volume 142, Issue 3, Pages (September 2016)

National trends in management of stage IIIC1 and IIIC2 uterine cancer: Chemotherapy and radiotherapy in isolation and sequence J. Chino, J.R. Foote,

Volume 146, Issue 1, Pages (July 2017)

Prognostic Factors in Patients with Pathologic T1-2N1M0 Disease in Non-small Cell Carcinoma of the Lung Katsunari Matsuoka, MD, Shinichi Sumitomo, MD,

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Pathologic response at interval debulking surgery following neoadjuvant chemotherapy predicts improved survival in women with ovarian cancer E.N. Prendergast,

Volume 151, Issue 1, Pages (October 2018)

Volume 70, Issue 1, Pages (July 2016)

K. Bixel, N. Denlinger, L. Marsh, A. Quick, R. Salani

Volume 152, Issue 1, Pages (January 2019)

Volume 143, Issue 2, Pages (November 2016)

Laparoscopic staging for stage I epithelial ovarian cancer: Analysis of the National Cancer Data Base A. Melamed, J.T. Clemmer, N.L. Keating, J.D. Wright,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

The origins of multidisciplinary cancer care

I. Mert, A. R. Munkarah, R. K. Hanna, J. Chhina, M. S. Carey, M

Volume 152, Issue 1, Pages (January 2019)

Segmentectomy for selected cT1N0M0 non–small cell lung cancer: A prospective study at a single institute Hiroaki Nomori, PhD, Takeshi Mori, PhD, Koei.

Are ovarian cancer debulking models reliable: Variance and predictability are dependent on institutional optimal debulking rates N.A. Latif, E.M. Ko,

Volume 130, Issue 1, Pages (July 2013)

Volume 152, Issue 1, Pages (January 2019)

Volume 147, Issue 1, Pages (October 2017)

Volume 152, Issue 1, Pages (January 2019)

Limited access safety lead-in of the MEK inhibitor trametinib in combination with GSK , an AKT inhibitor, in patients with recurrent or persistent.

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Volume 130, Issue 3, Pages (September 2013)

Volume 142, Issue 2, Pages (August 2016)

Annika Idahl, Andrea Hermansson, Ann Lalos Gynecologic Oncology

Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival: an NRG Oncology/Gynecologic Oncology Group study

Volume 152, Issue 1, Pages (January 2019)

Volume 130, Issue 1, Pages (July 2013)

Full inguinofemoral lymphadenectomy after positive sentinel inguinofemoral lymph node is associated with greater overall survival in patients with stage.

Volume 152, Issue 1, Pages (January 2019)

Volume 151, Issue 1, Pages (October 2018)

Upregulated Wnt signaling is associated with increased survival of patients with high- grade serous ovarian cancer M. Dandapani, B.L. Seagle, R. Samuelson,

Volume 130, Issue 1, Pages (July 2013)

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Esophageal Tumor After Radical Surgery for Gastric Cancer

Characteristics of primary peritoneal serous carcinoma in a U. S

Volume 147, Issue 3, Pages (December 2017)

Neal S Goldstein, MD The Annals of Thoracic Surgery

Should ovarian preservation be considered for women younger than 60 years with endometrial carcinoma? L.M. Bean, K. Taylor, K.M. Anderson, M.A. Davis,

Fig. 1. Kaplan-Meier curves for PFS and OS

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Volume 115, Issue 1, Pages (October 2009)

Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial.

Volume 154, Issue 1, Pages (July 2019)

Presentation transcript:

Volume 153, Issue 1, Pages 13-19 (April 2019) Analysis of gastric-type mucinous carcinoma of the uterine cervix — An aggressive tumor with a poor prognosis: A multi-institutional study Shin Nishio, Yoshiki Mikami, Hideki Tokunaga, Nobuo Yaegashi, Toyomi Satoh, Motoaki Saito, Aikou Okamoto, Takahiro Kasamatsu, Tsutomu Miyamoto, Tanri Shiozawa, Yumiko Yoshioka, Masaki Mandai, Atsumi Kojima, Kazuhiro Takehara, Eisuke Kaneki, Hiroaki Kobayashi, Tsunehisa Kaku, Kimio Ushijima, Toshiharu Kamura Gynecologic Oncology Volume 153, Issue 1, Pages 13-19 (April 2019) DOI: 10.1016/j.ygyno.2019.01.022 Copyright © 2019 The Author(s) Terms and Conditions

Fig. 1 Progression-free survival and overall survival: blue line, UEA group; red line, GAS group. Gynecologic Oncology 2019 153, 13-19DOI: (10.1016/j.ygyno.2019.01.022) Copyright © 2019 The Author(s) Terms and Conditions

Fig. 2 A: Survival curve of patients with pT1a-1b1 and pT1b1: PFS, progression-free survival; overall survival; blue line, UEA group; red line, GAS group. B: Survival curve of patients with pT1b2 and pT2: blue line, UEA group; red line, GAS group; N.S., not significant. Gynecologic Oncology 2019 153, 13-19DOI: (10.1016/j.ygyno.2019.01.022) Copyright © 2019 The Author(s) Terms and Conditions